TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

REIMAGINE DOSING AND ADMINISTRATION

TAKHZYRO is a subcutaneous (under-the-skin) injection that you give yourself once every 2 weeks. No reconstitution is needed.

Image of a man walking confidently. Rethink dosing and administration with TAKHZYRO.

Not an actual patient.

  • Image of a stopwatch.

    1MINUTETO SELF-INJECT for the majority of people

  • Image of marked calendar.

    EVERY2WEEKS

  • Image of a silhouette with injection sites highlighted.

    3CHOICESFOR INJECTION SITE Stomach (abdomen), either thigh, or either arm

The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO. If you have zero attacks for more than 6 months, your healthcare provider may prescribe you TAKHZYRO 300 mg once every 4 weeks.

It is important to take TAKHZYRO exactly as you have been trained.
Do not attempt to take it without first being trained by a healthcare provider.

SELECT IMPORTANT SAFETY INFORMATION

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.

Image of TAKHZYRO 300 mg/2 mL vial.

Dosing at a glance

TAKHZYRO C1-INH PREVENTIVE THERAPIES
Dosing schedule Once every 2 weeks
(starting dose)
Once every 3 to 4 days
How much 2 mL 4 to 25 mL*
Administration Subcutaneous injection Subcutaneous or intravenous injection/infusion
How supplied Ready-to-use, single-dose vial Reconstitution required

Table does not imply that one treatment is better than another, and does not include all possible HAE treatments. Please see full Prescribing Information for detailed dosage and administration information.

*Based on calculations from approved product Prescribing Information and patient weight assumptions.

TAKHZYRO should be kept in the refrigerator between 36°F and 46°F (2°C and 8°C).

SELECT IMPORTANT SAFETY INFORMATION

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

TAKHZYRO tips

Even if you experience fewer or no attacks during treatment, it is important to keep taking TAKHZYRO as prescribed by your healthcare provider. Remember not to skip a dose or alter your dosing schedule on your own.

  • To help you remember when to take your next dose, set a reminder on your phone or put a note on your calendar
  • You should also make sure you have your acute treatment on hand. Remember to periodically check the date to ensure that it hasn't expired

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • fast heartbeat
  • faintness
  • rash
  • hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see full Prescribing Information, including information for patients.